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Acidic fibroblast growth factor (aFGF) is a potent 
mitogenic and chemotactic agent for vascular endo-
thelial cells, dermal fibroblasts, and epidermal kera-
tinocytes, the principal cellular constituents of skin. 
To explore its potential to heal chronic dermal 
wounds, we applied pure recombinant human aFGF 
topically to full-thickness excisional injuries in heal-
ing-impaired genetically diabetic mice. Transforma-
tion of the nonlinear percent initial wound areas as a 
function of time to linear rates of tissue ingrowth 
from the original wound edges showed that aFGF 
increased wound closure in a dose-dependent man-
ner. Optimal 3-lLg/cm2 doses of aFGF nearly tripled 
G rowth factors that are mitogenic or chemotactic or that promote the difFerentiation of one or more types of cells that participate in the repair of injured skin could, in principle, promote cutaneous healing. The fibroblast growth wctors (FGFs) are a fami ly of 
nine known homologous mitogens [1-3] that stimulate cells of 
mesodermal and ectodermal origin through at least four unique 
membrane-spanning tyrosine kinase receptors and their alterna-
tively transcribed variants [4,5]. Acidic FGF (aFGF or FGF-1) 
appears to be unique among the characterized FGFs in its ability to 
bind all known FGF receptors with high affmity [5]. This broad 
receptor specificity presumably' contributes to its multiple cellular 
targets ill vitro and diverse therapeutically relevant biologic activities 
in animal models of tissue repair [6]. Pure aFGF is a potent mitogen 
for dermal fibroblasts [7,8], vascular endothelial cells [9], and 
epiderm al keratinocytes (7,10], the principal ceUs in skin. In 
addition, aFGF is chemotactic for vascular endothelial cells ill. IIitro 
[11] and induces new blood vessel growth ill IIillo [9,12] . We 
previously reported that aFGF accelerates the rate of healing of 
fuU-thickness dermal wounds in nonnal healthy rodents as reflected 
by enhanced granulation ti ssue deposition , vascularization, epider-
mal growth, and closure [13]. 
Chronic non-healing dermal ulcers are a serious problem in 
diabetic patients. The mutant C57BL/Ks-db/db diabetic mouse has 
emerged as a potentially re levant healing-inlpaired model for 
studying the effects of cutaneous wound-healing agents. These 
homozygous genetically diabetic mice develop obesity aJld hyper-
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the linear rate of healing. The median time to com-
plete closure decreased from 46 d in vehicle-treated 
wounds to only 16 d in those treated with aFGF. 
Histomorphometric analyses established that aFGF 
increased granulation tissue formation and reepithe-
lialization throughout healing. Vehicle- and aFGF-
treated wounds appeared to be histologically equiv-
alent by the time of closure. Therefore, aFGF has 
potential therapeutic applications for promoting 
healing of dermal ulcers, especially in healing-im_ 
paired individuals. Key words: impaired heaUttglallgio_ 
gellesisldiabeteslwOlmd closltye. ] Invest Dermatol 104:850-
855, 1995 
glycemia that is resistant to insulin, analogous to humaJl type II 
diabetes [14]. They also show signs of diabetes 'such as excessive 
drinking and urination and greatly elevated urinary glucose levels. 
Wounds in these mice exhibit a marked delay in cellular infiltra-
tion, granulation tissue fonnation, and wound closure [15-22]. 
Previous studies have used this model to evaluate formulations of 
aFGF [21,22]. In this report, we show that recombinant human 
aFGF markedly accelerates the rate of healing of fuU-thickness 
excisional dermal wounds in diabetic mice aJld describe the histol-
ogy of the response. We also originally demonstrate that the rate of 
tissue ingrowth from wound margins in this model of impaired 
healing is constant with time, providing an objective measure of 
linear healing kinetics. In addition, aFGF is shown to accelerate the 
rate ofLinear ingrowth and substantially decrease the .time required 
to achieve tota l closure . 
MATEIUALS AND METHODS 
Growth Factors Human recombinant aFGF was prepared as described 
[23]. Briefly, a synthetic gene encoding the 140 amino acid protein was 
expressed in Escherichia coli, and the recombinant product was purified 
chromatographically to apparent homogencity. Pure aFGF was formulated 
in phosphate-buffered salinc (PBS) with a threefold mass excess of porcine 
heparin (Sigma), which binds and stabilizes the protcin. The mitogcnic 
activity of aFGF was measured by full dose-rcsponse DNA-synthesis assays 
using Balbi c 3 T3 fibroblasts [24]. 
Skin Organ Culture Full-thickness shaved skin biopsy specimens 6 mm 
in diameter, removed from diabetic mice at wounding, were p laced in organ 
culture as described [13] . Briefly, tissue samples were incubated at 37°C in 
Dulbecco's modified Eagle's medium (Gibco) supplemented with 0.25% 
heat-inactivated bovine serum (Gibco) and 50 /Lg/m 1 heparin. The skin 
specimens were treated daily for either 2 or 3 d with 0,1,10, and 100 /Lg/ml 
aFGF. They were then labeled for 24 h with 4 /LCi of[lIIethl'/-' Hlthymidine 
(20 Ci/mmol; New England Nuclear). After thymidine labeling, the 
specimens were washed, solubil.ized, and counted as described [13] . 
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Animals Female Cs7BLlKs-db/ db diabetic mice , 11 weeks old, were 
obtained from Jackson Laboratories (Bar Harbor, ME) . T he nuce were 
housed in steril e microisolator boxes (four per box) with sterile water and 
bedding and were kept in a semi-barrier quarantine facili ty. Supplemental 
heat was provided with electric heating pads under half of each box after 
wounding to prevent hypothermia and reduce mortali ty. All studies were 
conducted in accord with the rulcs and guidelines of the Merck Research 
Laboratories Institutional Animal Care and U se Committee and the "Guide-
lines for the Carc and Use of Laboratory Animals" (DHHS Publication 
[NIH] 85- 23, rev ised 1985). 
Wound-Closure Modcl Mice were anesthetized with intraperitoneal 
injections of 110 mg kctam in e and 9 mg xylazine per kg of body weight. 
T he mid-back and thoracic skin was shaved and disinfected with a 2% 
Chlo rhexidine surgical scrub (N olvasan ; Aveco, Ft. Dodge, IA) followed by 
70% ethanol. A template 1.6 cm in diameter was used to mark a 2.0-cm2 
circlc on the mid-dorsa l area, and a single full-thickness wound was created 
by blunt excision with sterile curved ir is scissors. Wound areas typically 
increascd to approximately 2.3 cm 2 soon after inju ry, presumably because of 
con traction of the dermis along the wound perimeter. All surgical and 
subsequen t healing analysis procedures were performed in a laminar flow 
hood using full aseptic techniques. Filter-sterilized growth factors and 
corresponding vehiclc con trol solutions were applied topically. Doses (28 
JLI) were administe red after injury (day 0) and 3 and 7 d later. The wounds 
were covered with a semitransparent Bioclusive dressing Oolmson & 
jolmson Products , N ew Brunswick, NJ) for protection, maintenance of a 
moist environment, and prevention of crust fonnation . Wound fluid 
samples werc taken at day 10 after injury and cultured for aerobic and 
anaerobic microorganisms. Animals from wluch cultures exhibited more 
than 50 colonies per wound were excludcd from the study analysis. 
Prevention of even mild or subcluucal in fection resulted in a consistent 
maximal hca ling impairment, thus providing a large wound-healing WU1-
dow for eva luation of treatment effects. 
Hcaling Analysis Wound appearances were recorded photographically, 
and the ir perimcters wcre traced onto stcrile glass slides applied directly to 
thc exposed wound surf.1ces after prewetting with a drop of sterile 
physiologic sa line . Measurements were made immediately after wounding 
and twice weekly thereafter until the wounds were comple tely closed. 
Wound areas and perimeters were determined fro m the glass-s lide tracings 
using compu te rized image anal ysis (Presage C V-6; Advanced Imaging 
Concepts, Princeton, NJ). Statistical signific'mces of differences between 
groups were evaluated using an unpaired two-tail ed Student t test. 
Hea ling expressed as a decrease in percent uutial area was convertcd to 
linear ingrowth from thc wound edges by dividing the difference in wound 
areas by the average wound perimeters at sequcntial time in tervals. Tota l 
ingrowth at a specific time is the sum of the incremental ingrowth distan ces 
up until tha t ti me. T his transformation linearized closure as a function of 
time, thereby allowing express ion of healing as kinetic rates that were 
constan t over time. A similar analysis, independently proposed by H opkins 
and J amieson [25J and latcr modified by Gilman [26], has been used to 
determine the linear rate of healing of diabetic and veno us stasis leg ulcers 
[25,27,28]. Slopes of linear healing curves for individual a1umals were 
determined by regression ana lysis and analyzed statistically USUlg an lll1-
paired two-tailed Student t test. 
Wounds, examined twice weekly to mOlutor time to tota l closure, were 
considered fully hea led when moist granulation tissue was no longer 
apparent, indicating a functional ep idennal water-permeabili ty barrier . 
C losure was also confirmed lustologically. Time-point comparisons of the 
fraction of hea led "e,.s lIs unhealed wounds were analyzed by tlle K statistic 
with Yates correction, and group comparisons of absolute days to total 
closure for individual animals were ana lyzed by an unpaired two-tailed 
Studen t t test. 
Histologic Analysis After sacrifice by CO 2 inhalation, the mice were 
eviscerated and fixed ovenught in 10% Zn forma lin (Anatech, Battle C reek, 
MI) . Wound tiss ue was removed Witll adjacent unwounded skin and 
underlying fasc ia and muscle. T he backbone was included to stabilize the 
wound tissue and maintain normal geometry for later histomorphometric 
measurements . T he tissue was decalcified ovenught in Cal-EXlI (Fischer 
Scientific, Orangeburg, NY) and bisected through tllC center. T he halves 
were then cmbedded in paraffin, and s-JLm-tlUck sections were cut. Central 
sections through tile wound were deparaffinized, cleared, rehydrated, and 
stained with Masson trichrome. 
Morphometric analyses of represcntative mid-wound lustologic sections 
were donc using a Presage CV-6 image analyzer. Images were captured 
w ith a color video camera mounted on a microscope and displayed on a 
high-resolu tion monitor. Granulatio n tisme zones in the wound bed, 
identifIed by the abundant blood vessels between the edges of unwounded 
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F igurc 1. aFGF induccs a mitogcnic rcsponsc in culturcd diabetic 
Inousc skin biopsy spccinlcns. Full-th.ick1less Skitl specimens 6 mm in 
diameter were incubated at 37°C Ul 0.25% heat-inactivated bovine serum 
and 50 JLg/ ml heparin and treated daily for either 2 d (sqlla,.es) or 3 d (circles) 
w ith 0, 1, 10, or 100 JLg/ ml aFGF. One day before harvest, 4 JLCi of 
[met(,)'l-' H]tllymidine was added. Unincorporated thymidine was removed, 
the tissues were digested , and radiolabel incorporation was detemuned by 
scintillation coun ting. Data are p lotted as mean ::!: SEM (n = 6 per group). 
' p :s 0.05; " p :s 0.01 bi' unpaircd, two-tailed t test. 
dermal tissue, were traced using a digita l drawing board. Unwounded 
demlis was identified by its characteristic highly organized collagen fibril 
staining. Wound contraction was assessed by measuring the distance 
between these un wounded margins at a l11id-dermal level. T he lengtl1S and 
cross-sectional areas of new epidermis werc also measured. 
RESULTS 
aFGF Induces DNA Synthesis in Skin Organ Cultures Di-
abetic mouse 6-mm full-thickness skin biopsy specimens incorpo-
rated [lIl cthyl-3H]thymidine in response to daily aFGF doses of 0, 1, 
10, and 100 /-Lg/ ml, with a clear response peak seen at 10 /-Lg/ ml 
(Fig 1). T h erefore, cells within the skin responded mitogenically to 
aFGF as a function of dose. The highest concentration of aFGF 
resulte d in suboptimal incorporation of radiolabel, an effect noted 
earlier in normal rodent skin [13] and in monolayer cell cultures 
[23] . P lugs re m ained viable for 4 d, after which they deteriorated 
both in ability to incorporate thymidine and in structural integrity. 
aFGF Accelerates Wound Closure in Diabetic Mice Full-
thickness d e nnal excisiona! wounds 1.6 cm in diameter closed 
substantia lly faster in response to three doses of 3 /-Lg aFGF per cm2 
initial wound area administered during the first week after wou.nd-
ing compared with treatment with the corresponding vehicle 
con tro l (Fig 2a) . Statistica.ll y significant enhancements of the 
healing rate (p :5 0.01) of aFGF- treated wounds were seen as early 
as day 7 after injury and continued throughout the test period. A 
50% m aximum difference in p ercent of initial area between aFGf.· 
and vehicle-treated wounds occurred from 10 to 14 d after injury. 
T his difference corresponded to a 12-fold decrease in wound size in 
aFGF-treated mice at day 14 compared with those receiving the 
correspond.ing PBS/ heparin vehicle. Althou g h wounds receiving a 
liquid vehicle h ealed som ewhat faster than wounds receiving 
n othing, treatment with e ither PBS or normal saline resulted in 
h ealing rates equivalent to those with the h eparin-containing PBS 
vehicle (data n ot sh own). 
As shown in Fig 2a, wowld closure was nonlinear as a function 
of time, so th e magnitude of the effect of aFGF treatment appeared 
to ch ange over time. Becau se th ese full-thickness wounds closed by 
progressive h ealin g from the wound perimeter, we transformed th e 
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Figure 2. Diabetic mouse excisional wound closure is accelerated 
by aFGF. a) Circular fu ll-thickness wounds 1.6 cm in diameter were 
treated on days 0, 3, and 7 after injury with either 3 /-Lg/cm2 aFGF 
containing a th.ree-fold mass excess of heparin in PBS (sqllares) or with the 
corresponding PBS-heparin vehicle (circles) . Mean (~SEM) wound arcas are 
plotted as percent of initial WOUild area; error ranges smaller than the 
symbol size are not shown (n = 40 per group) . aFGF-treated groups were 
signjficantly different (Student unpaired two-tailed t test, p ,:; 0.01) from 
their respective vehicle-treated controls at all times after day O. b) Wound 
closure calculated as the cumulative average distance (mm) that the new 
tissue grew in from the wound edges as a function of time after injury. These 
data are transformed from data in a by dividing the difference in wound 
areas at two intervals by the average of their perinleters and then adding 
these differences from time O. The vertical axis full scale (8 mm) corre-
sponds to complete closure of the wounds. 
data from percent initial wound area to average linear healing 
length from the original wound edges. As seen in Fig 2b, this 
ca1culation linearized the average h ealing rates after an initial 3-d 
lag. Treatment with aFGF signifi can tly (p :::; 0.01) increased the 
linear rate of healing from the wound edges at all time intervals. 
The slope of cumulative linear healing length as a func tion of time 
was determined for each animal. T hese slopes, gro uped by treat-
m ent, showed that 3 .0 J.Lg/cm 2 aFGF increased the mean linear 
healing rate to 0.55 mm/d, from 0.20 Il1m/ d observed in · the 
vehicle-treated group (p :::; 0.01) . 
Treatment with this dose of aFGF also clearly reduced the time 
to total wound closure . Statistically significant (p :::; 0.05) increases 
in total closure were seen by day 1.4 (Fig 3). T he median time to 
complete closure decreased from 46 d in vehicle-treated wounds to 
only 16 d in those treated with three doses of aFGF during the first 
w eek after injury (p :::; 0.0001). 
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Figure 3. Tittle to complete closure of diabetic mouse excisional 
wounds is reduced by aFGF. The percentage of wounds remaining open 
at each time point is plotted for the vehicle-treated (circles) and aFGF-treated 
(sqllares) groups dosed topically on day 0, 3, and 7 after injury (n = 40 per 
group) . ' p ,:; 0.05; " p ,:; 0.01 by X2 with Yates correc tion. The decreased 
time to tota l closure in the aFGF "erslls the vehicle group (p ,:; 0.0001) was 
detemlined using Student unpaired two-tailed t test. 
Enhancement of Wound Healing by aFGF is Dose Depen-
dent Three topical applica tions of aFGF, ranging from 0.1 to 10 
J.Lg/cm2 per '')se, applied during the first w eek after injury resulted 
in si gnifi can , dose-related increases in healing rates over paired 
vehicle controls (Fig 4a) . T he 0.001-J.Lg/cm2 (not shown) and 
0.01-J.Lg/cm2 doses were ineffective, thus establishing a "no effect" 
level between 0.01 and 0.1 J.Lg/ cm2 • A sma1l but detectable 
accelerated healing response was also seen in the 10-J.Lg/cm2 
vehicle group, probably because of the heparin content of the dose 
(30 J.Lg/ cm 2 ) which , in contrast to lower doses, resulted in substan-
tial bleeding and therefore exposure to blood-bome growth factors. 
A dose-response relation was also seen in the time to comple te 
wound closure (Fig 4b). Application of aFGF from 0.1 to 10 
J.Lg/ cm 2 per dose significantly reduced the time required for these 
wounds to close completely. In the dose range of 0.6 to 3.0 
J.Lg/cm 2, wounds closed approximately 30 d sooner than their 
respective vehicle controls. As seen for the closure rates, the 
0 .001-J.Lg/cm2 (not shown) and 0.01-J.Lg/cm2 doses were ineffec-
tive in decreasing the time to total closure . T he accelerated healing 
rate seen in the 10-J.Lg/cm 2 vehicle group (i.e ., 30 J.Lg/cm 2 heparin) 
also resulted in a decreased time to total closure. 
aFGF-Treated Wounds Change in Gross Appearance and 
Histomorphometry Figure 5 shows changes in the gross ap-
pearance and m ean size of vehicle- and aFGF-treated wounds from 
mice immediately after injury and 5, 10, and 15 d post-injury. As 
early as day 3 after injury and the initial application of 3 .0 J.Lg/ cm 2 
of aFGF, wounds showed a visible reddening and leakage of serous 
fluid, possibly due to capillary leakage associated with neovascu-
larization. By day 5, these characteristics were even more pro-
nounced. Wounds receiving only vehicle contained little or no 
visible serous fluid and substantially less apparent neoangiogenesis. 
As observed previously in normal rodent wounds [13], histologic 
m easurem ent of the widths of the diabetic wounds between the 
edges of the uninjured dermis indicated that aFGF did not alter 
wound contraction (data not shown). Histomorphometric evalua-
tion of the wounds demonstrated that a.!though aFGF had only a 
modest effect o n the growth of new epidemlis (Fig 6a,b) at 5 dafter 
injury, it stimulated a 19-fold increase in granulation tissue cross-
sectional area (p :::; 0.05; Fig 6c). By day 10 after injury, a three- to 
fourfold improvement was observed in reepithelializa tion (p oS 
0.01) , w ith greater than a fourfo ld increase in granulation tissue 
formation (p :::; 0.01). At day 15, granulation tissue area of 
aFGF-treated mice was less than twofold larger than that in 
vehicle-treated mice . Tllis diminished difference could be due to 
tissue remodeling associated with maturation of the aFGF-induced 
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Figure 4. aFGF induces a dose-dependent increase in diabetic 
ntouse wound healing. Data for aFGF-treated (squares) and the corre-
sponding PBS-heparin vehicle-treated (circles) groups are plotted 011 a log 
scale as a function of dose . • p :S 0.05; • • p :S 0.01 by unpaired, two-tailed 
t test. a) Mean (:!::SEM) linear healing rate; b) mean ( :!:: SEM) days to total 
closure. 
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granulation tissue in largely closed wounds. In contrast, by day 15 
epithelial area and length were increased four- to sixfold (p :5 0.05) 
by aFGF treatment. Therefore, the increased closure that occurred 
by day 15 in aFGF-treated wounds could have been the conse-
quence of deposition and maturation of granulation tissue, which 
facilitated subsequent coverage by epithelium. Epidermal and der-
mal thickness in addition to dermal collagen fibril maturation and 
organization of fully healed vehicle- and aFGF-treated wounds 
were virtually indistinguishable by gross histology. Therefore, 
despite substantially accelerated healing, aFGF promoted a mor-
phologically normal tissue-repair response. 
DISCUSSION 
Skin organ cu1ture studies with radiolabeled thymidine clearly 
showed that aFGF is capable of stimulating DNA synthesis in the 
skin of db! db mice. Tllis result was comparable to the response that 
we had seen previously in nonnal rodent skin [13] and suggests that 
aFGF might promote dermal healing in these animals. Indeed, we 
found that aFGF substantially accelerated the closure of full-
t1lickness excisional wounds in healing-impaired diabetic nUce. A 
maximal twofold decrease in wound area was seen previously in 
aFGF-treated nomlal mice compared with vehicle-treated controls 
[13], whereas in the present study, a 12-fold improvement was seen 
in the diabetic mice at 2 weeks after injury. Therefore, the efficacy 
of aFGF appears greater in healing-impaired alUmals, perhaps in 
part as a result of t11eir slower spontaneous healing. 
The commonly used nonlinear measure of wound closure-
reduction in percent initial open wound area-decreased rapidly 
during the early phases of healing but slowed as the wounds 
approached closure, giving the impression t11at aFGF is most active 
in the initial stages of healing. However, transfonned to tissue 
ingrowth from the wound edges, healing was seen to proceed at a 
constant rate throughout closure, independent of the size of the 
wound. Evaluation of healing as a function of dose using this 
method demonstrated that an optimal 3 f.Lg! cm2 of aFGF promoted 
nearly a threefold increase in the rate of linear closure, with a 
correspondillg approximate threefold decrease in the time to total 
closure. 
Topical application of aFGF resulted in a substantial enhance-
ment of granulation tissue formation , followed by migration of 
epidemlis to acllieve significantly earlier total closure. Near closure, 
granulation tissue cross-sectional area decreased, presumably be-
cause of remodeling associated with maturation. Evaluation of fully 
closed vellicle-control- and aFGF-treated wounds indicated no 
significant difference in epidermal or demlal t1lickness or in dermal 
Day 15 
Figure 5. Healing of aFGF-treated 
excisional wounds is readily appar-
ent ntacroscopically. Wounds (1.6 
cm initial diameter) were treated with 
either the PBS-heparin vehicle or 3.0 
J.tg/ cm2 aFGF on days 0, 3 , and 7 after 
injllry and were photographed 011 days 
0, 5, 10, and 15 . Representative 
wounds are from a) vehicle-treated an-
imals and b) aFGF-trcated animals. A 
50% maximal difference in percent ini-
tial area betwecn aFGF- and vehicle-
treated wounds is evident at days 10 
and 15 after il1iury. Bar, 10 mm . 
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Figure 6. aFGF enltances wound reepithelialization and granula-
tion tissue deposition in the diabetic mouse. Wounds were treated 
with placebo or 3.0 /Lg/cm2 aFGF on days 0, 3, and 7 after injury. 
Mid-wound sections 5 J.Lm thick were stained with Masson trichrome. Mean 
:t SEM data are plotted for aFGF- treated (sqlfares) and velllcle-treated 
(circles) groups. a) Epidermal cross- sectional area; b) epidermal length; c) 
granulation ti ssue cross-sectional area at 5, 10, and 15 d after injury. ' p :5 
0.05; " p :5 0.01 by unpaired , two-tai led t test. 
collagen fibril maturation and organization. Therefore, aFGF treat-
ment led to healed tissue that appeared histologically normal. 
The efficacy of aFGF is mediated through one or more trans-
membrane tyrosine kinase FGF receptors (FGFRs). Mitogenic 
responses to FGFs are attributable to four known receptors (FGFR1 
through FGI'R4) , the first three of which are subj ect to alternative 
transcription of exon In encoding the C-tenni.nal half of the 
extracellular immunoglobulin ligand-binding domain proximal' to 
thc membrane. Alternative ly spliced exon IITb forms, all preferen-
tially expressed in skin, retain their tight bindulg to aFGI' but bind 
basic I'GF (bI'GI') with either substantially lower affinity or not at 
all [5,29-31) . The alternatively transcribed exon IIIb version of 
I'GI'R2, but not I'GFR3, also binds keratinocyte growth factor 
(KGF or FGI'-7) with high affinity and is the predominant fonn of 
I'GI'R2 in diabetic mouse skin [32]. Its expression by epidermal 
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keratinocytes could account for their greater mitogenic responsive-
ness to aFGF as compared with bFGI' [8] . Selective epidermal 
expression of a dominant-negative truncated form of tlus receptor 
resulted Ul epidermal atrophy, a decreased number of hair follicles, 
and compromised wound reepithelialization in transgenic mice 
[33]. 
In contrast, the widely distributed, alternatively transcribed 
forms ofFGFR1 and FGFR2 incorporating exon lIIc, expressed on 
fibroblasts and vascular endothelial cells, bUld aFGF and bFGF with 
similar affinities, as reflected by their comparable l1utogenic poten-
cies on these cells, but do not recogJuze KGF. Epidennal expression 
'of truncated dommant-negative I'GFR1-IIlc, wluch can fonn non-
functional heterodimers with several different full-length FGFRs, 
resulted in aberrant keratinocyte differentiation and keratul expres-
sion in transgenic nUce [34] . Because KGI' does not bind to the IIIc 
fonn of this receptor, other epidermally expressed FGFs such as 
aFGI' released by keratinocyte death might also normally function 
in the epidennis. Therefore, exogenous aFGI', wluch binds with 
high affinity to both the exon IlIb and IIIc fonns of FGFRs, should 
be uniquely able to supplement the activities of not only endoge-
nous aFGF but also bFGF and KGF . 
As in diabetic humans, the etiology of the healulg unpairment Ul 
diabetic mice is not entirely clear. The expression of FGF and 
FGFR mRNAs has been characterized Ul response to fuU-thickness 
excisional skin wounds in normal [35] and diabetic [32] mice. In 
nornlal animals, aFGF and bFGF mRNAs increased 10- and 
fourfold, respectively, within 1-5 d of wounding and returned to 
nonnal low levels within 1 week of injury. In contrast, expression 
of KGF mRNA increased 160-fold witllin 1 d of injury and 
remained approximately 100-fold elevated 1 week later. KGF 
mRNA expression was localized witllin the demus, whereas KGF 
receptor (FGFR2-IIIb) mRNA was selectively expressed Ul the 
KGF-responsive epidermis. In excisional wounds of healing-un-
paired db/db diabetic mice, KGF mRNA peak expression is 
enhanced only five- to tenfold and is delayed 2-4 d. Furthermore, 
ulcreased expression ofaFGF and bFGF in db/db wOlUlds was also 
found to be short-Lived, and FGFR mRNA leve ls declined 
throughout the first week after injury . Thus, diminished FGF 
function could contribute to impaired healing in the db/db mouse 
and might help explai1l the efficacy of exogenous aFGF. 
In addition to decreased ulduction of endogenous FGFs and , 
perhaps, other growth factors, the impaired healing could be 
related to delayed migration of inflammatory ceUs and fibroblasts 
into the wound as a consequence of suppressed immune function Ul 
these mice [16,18 ,36]. These mi ce are reported to have an abnor-
mally small spleen and thymus as weU as elevated levels of plasma 
corticosterone [18,37), wluch might delay healing in a manner 
similar to that of unmunosuppressive glucocorticoids [19,37]. Im-
munosuppression might also facilitate ulfections that could lead to 
the inconsistent healing responses reported in velucle control 
wounds in earlier aFGF studies [21,22] . We have observed that 
such infections can cause erratic acceleration of wound closure, 
possibly by stimulating ceUular infiltration of immune cells. Bacte-
ria-enhanced healing of normal rat incisional wounds has been 
reported recently. * Although not clinically desirable, infection-
induced heawlg could be secondary to the general inflammatory-
response-mediated release of a variety of stimulatory cytokines, 
including some known to promote angiogenesis. 
Although wounding and dOSUlg protocol differences prevent 
direct comparison with aFGI', unprovements in healing have also 
been seen in response to other growth factors in the db/db mouse. 
Topical doses ofbFGF were reported to promote excisiona! wound 
healing [16,20]. Between 12 and 18 d after injury, hFGF-induced 
granulation tissue t1uckness decreased and matrix density ulcreased 
[15], suggesting tissue remodeling and maturation similar to that 
which we observed in these studies. Human recombinant platelet-
• WiUiams WG, Hollyoak M, Heggers JP, Robson Me, Phillips LG , 
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derived growth factor-BB has also been reported to be an active 
healing agent in the db/db model [16,17]. Although a single topical 
dose of platelet-derived growth factor-BB was ineffective, five 
consecutive daily doses resulted in a significant improvement in 
closure rate at day 21. Both mitogens also have been shown to 
reverse the healing impairment in protein-malnourished db/db 
diabetic mice [38], a pertinent observation given that malnutrition 
can also compromise tissue repair in humans. However, no reports 
are avaiJable on the effects of either bFGF or platelet-derived 
growth factor on the clinicalJy relevant parameter of time to total 
wound closure. 
The impairment in healing of full-thickness wounds in diabetic 
mice is a reproducible and potentially important model for deter-
mining growth factor clinical efficacy. Human aFGF has been 
demonstrated to accelerate full-thickness excisiona! wound repa.ir 
and to shorten the time to complete closure in tills model. Thus, 
aFGF has potential therapeutic applications for the cl.in.ical treat-
ment of ChrOlllC non-healing dermal ulcers resulting from condi-
tions, such as diabetes, that impair nonnal healing. 
We II"lIIk Robel1 MCll llicfor lec/mical help ill allilllallwlldlillg proadllrcs alld lracillg 
lII easllrelllellls, Marie-T herese Sc/wtd!cr for eOlldllelillg Balblc 3T3 lIIilogellie lisslle 
wltllre assays, alld Charlollc Traillor for lIaelelial ,volllld wltllres. 
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